Although AMPK activation has been proposed as a promising molecular target for treating obesity and its related comorbidities, the use of pharmacological AMPK activators has been met with contradictory therapeutic challenges. Here, PRKAA2 is linked to obesity due to melanocortin 4 receptor deficiency.